Clinical trials show pembrolizumab active against mucosal melanoma, extends survival in bladder cancer.
The US Food and Drug Administration has approved nivolumab (Opdivo) for the treatment of patients with locally advanced or metastatic bladder cancer.
Faced with a harsh treatment option, a patient with genitourinary cancer helps create a treatment plan that preserves his self-image.
Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.
A recent study undertaken sought to examine the effects of chemotherapy on bladder cancer cells and possible connections to later treatment resistance.
Single-agent nivolumab induced durable clinical responses with a manageable safety profile in previously treated patients with locally advanced or metastatic urothelial carcinoma.
Emulsifying Mycobacterium brumae in olive oil appeared promising for producing a robust immune response in preclinical tests. Recent research has indicated that M brumae is a safer alternative to BCG.
US FDA granted accelerated approval to atezolizumab (TECENTRIQ), indicated for the treatment of locally advanced or metastatic UC in patients whose disease progressed during or following platinum-based chemotherapy, or in the neoadjuvant or adjuvant setting.
Researchers believe arsenic exposure might contribute to higher-than-normal rates of bladder cancer in the region.
Pioglitazone use correlated with increased rates of bladder cancer across a large population. The risk of developing bladder cancer also increased with higher dose and longer use of the drug.
A bladder preservation rate of 83% occurred at 3 years after a trimodality treatment approach for localized bladder cancer that used adaptive image-guided, intensity-modulated radiation therapy (IG-IMRT).
Guideline on muscle-invasive and metastatic bladder cancer, with qualifying statements
Recent developments in a gas chromatography tool might allow doctors to determine whether urologic cancers are present via a urine sample.
Adjuvant chemotherapy was associated with improved survival in patients with locally advanced bladder cancer.
Mental health status prior to bladder cancer surgery may be associated with postoperative outcomes.
A novel immunotherapeutic approach improved outcomes for patients with advanced bladder cancer, according to a recent study.
Researchers developed a way to personalize treatments for aggressive bladder cancer. Taking bladder tumors from individual patients, identifying actionable mutations, and grafting the tumors into mice, researchers were able to simultaneously test multiple therapies in the tumor models.
Although some previous studies have suggested an increased risk of bladder cancer with use of the diabetes drug pioglitazone, additional analysis has not found a statistically significant increased risk.
Older white males with advanced bladder cancer are the most likely to commit suicide among patients with genitourinary cancers.
A newly developed urine test could help to guide clinicians in the treatment of bladder cancer patients.
The long-term survival rates following laparoscopic surgery for bladder cancer are not unlike survival rates for open surgery, according to research.
The antibody MPDL3280A, which blocks the protein PD-L1, resulted in tumor shrinkage in slightly over half of tested patients with advanced bladder cancer.
Long-term survival rates following laparoscopic surgery for bladder cancer are comparable to those of open surgery, according to recent study data.
There is no link between either pioglitazone or rosiglitazone and bladder cancer.
Patients with stage 2 or higher urothelial carcinoma who underwent a care transition more likely to experience a delay in treatment.
Researchers have demonstrated for the first time that the quality level of diagnostic staging using biopsy in patients with bladder cancer is directly linked with their survival.
Active smokers more knowledgeable than former smokers or nonsmokers, and often cite urologist as source of information.
In cases of bladder cancer, omission of muscle in specimen or its mention in pathology report is linked to increased mortality.
According to new research, invisible blood in the urine may be able to be used to diagnose bladder cancer.
Scientists have identified a protein that could help doctors decide which patients with bladder cancer would benefit from a treatment that makes radiotherapy more effective, according to a new study.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|